Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Summary

Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment. This study will enroll approximately 90 male and female subjects clinically diagnosed with Tourette Syndrome.

Timeline

Start

2015-11

Primary completion

2016-12

Completion

2016-12

Drugs

Indications